Schrödinger to Present Data from Its MALT1 Inhibitor Program at the American Society of Hematology (ASH) 2020 Annual Meeting
Summary
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced it will present data from its preclinical MALT1 inhibitor program at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition to be held virtually December 5-8, 2020. “ We look forward to sharing our updated MALT1 results and advancing the program to IND-enabling studies in the coming year,” said Karen Akinsanya, Ph.D., Executive Vice President, Chief Biomedical Scientist and Head of Discovery R&D at Schrödinger. Our physics-based software platform helped to accelerate compound optimization, enabling candidate selection in under two years.” The abstract is available online on the ASH website and will be presented at the poster session in December. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. Schrödinger’s multidisciplinary drug discovery team also leverages its software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.
Classifications
AskAI Classifications
LabelsLinked Companies
